SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing a significant surge in momentum driven by a combination of index rebalancing, active share buybacks, and high short interest that has led the community to draw parallels to previous parabolic short squeeze setups. Traders are closely monitoring a tight, institutional-heavy float as they anticipate that sustained upside could force short sellers to cover, potentially accelerating price movement toward key resistance levels.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is currently in the spotlight following the FDA accelerated approval of Trutakna for primary IgA Nephropathy, a major clinical milestone that validates its commercial trajectory in the kidney disease space. While the stock has seen muted price action, the community is actively debating the significance of the broad label and potential for future commercial uptake against existing competitors.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors anticipate a major catalyst from the Phase 3 COMP006 trial readout for its depression therapy, which is fueling optimism about a potential FDA approval and commercialization. The community is heavily focused on the stock's recent recovery and institutional accumulation, with many discussing the long-term potential for COMP360 to disrupt the mental health sector and the possibility of future acquisition interest.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is currently trending as investors focus on the potential for a multi-billion dollar patent litigation settlement with Pfizer and the strategic value of the companys LNP patent portfolio. The community is actively debating the stock's significant undervaluation, with many highlighting recent institutional accumulation and the potential for a major valuation re-rate following imminent clinical and legal catalysts.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors debate the potential implications of a proposed acquisition of eBay, with community discussions heavily split between optimism over strategic growth and skepticism regarding the dilution required to finance such a deal. Despite recent positive earnings reports, many remain focused on the company's long-term pivot strategy, with ongoing speculation about shareholder dilution and the impact of the digital-first shift in the gaming industry.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trending as investors debate the stock's role as a critical AI infrastructure and data-layer provider versus broader concerns regarding international security policies and market valuations. The community is actively discussing the stock's potential for institutional re-rating, its strategic partnerships with firms like Nvidia, and the long-term outlook for enterprise AI adoption.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing significant volatility as investors weigh a surprise 75-million-share stock offering against better-than-expected revenue guidance and strong delivery numbers. The community is sharply divided, with some highlighting the necessity of raising capital to meet equity-matching requirements for a government loan and scale production, while others criticize the dilution as a recurring obstacle to long-term price appreciation.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is currently trading as a high-conviction merger arbitrage play following the announcement of a definitive agreement for Vertex Pharmaceuticals to acquire the company in an all-cash deal. Investors and community members are actively discussing the significant buyout premium and evaluating the strategic expansion of Vertex's rare-disease portfolio as the stock stabilizes near the final acquisition price.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare Inc. (NET) is generating significant momentum as analysts highlight its critical role in the AI infrastructure landscape and edge computing market. Investors are closely monitoring the stock's consolidation patterns near all-time highs while engaging in active debates regarding its aggressive growth strategy and positioning as a foundational layer for autonomous AI agents.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors digest a positive earnings report that highlights rapid revenue growth and a raised full-year outlook, fueling community speculation about a potential buyout. While supporters emphasize the long-term potential of the Recorlev franchise and the upcoming Phase 3 trial for the subcutaneous levothyroxine candidate XP-8121, others remain cautious, citing frustrations with management's communication and recurring delays in pipeline milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer Conference

UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Mitchell Rock, President and Chief Executive Officer, and Ron Lataille, Sr. Vice President, Treasurer and Chief Financial Officer, will present and host 1x1 meetings at the CJS Securities 26th Annual New Ideas Summer Conference on...

UFP Technologies Director Sells $287,000 After Option Exercise as Shares Stay Flat

Key PointsA director of UFP Technologies sold 1,200 shares for approximately $287,000 on June 12, 2026, via an option exercise and immediate disposition at around $239.29 per share...

UFP Technologies to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10th in New York, NY

UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Mitchell Rock, Chief Executive Officer, and Ron Lataille, Sr. Vice President, Treasurer and Chief Financial Officer, will present at the East Coast IDEAS Investor Conference on Wednesday, June 10, 2026 at The Westin Times Square in New...

UFP Technologies Names Ryan Stafford General Counsel and Senior Vice President of Human Resources

UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization specializing in single-use and single-patient medical devices, today announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026...

UFP Technologies (NASDAQ:UFPT) Sets New 52-Week Low  - Here's Why

UFP Technologies (NASDAQ:UFPT) Reaches New 12-Month Low - Here's Why...

UFP Technologies Q1 Earnings Call Highlights

UFP Technologies (NASDAQ:UFPT) reported first-quarter 2026 results that management said reflected a solid start to the year, led by continued growth in its medical business and progress on strategic...

UFP Technologies (NASDAQ:UFPT) Shares Gap Down   - Time to Sell?

UFP Technologies (NASDAQ:UFPT) Shares Gap Down - Here's Why...

UFP Technologies (UFPT) Tops Q1 Earnings Estimates

UFP (UFPT) delivered earnings and revenue surprises of +13.76% and -2.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

UFP Technologies (NASDAQ:UFPT) Issues Earnings Results

UFP Technologies (NASDAQ:UFPT - Get Free Report) announced its quarterly earnings data on Monday. The industrial products company reported $2.48 earnings per share (EPS) for the quarter, beating...

UFP Technologies Announces Strong Q1 Results

UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $17.5...

UFP Technologies, Inc. engages in designing and custom manufacturing of components, subassemblies, products and packaging utilizing specialized foams, films, and plastics primarily for the medical market. The firm manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding and fabricating manufacturing techniques. Its products include military uniform and gear components, automotive interior trim, athletic padding, environmentally friendly protective packaging, air filtration, abrasive nail files, and protective cases and inserts. The company was founded by Richard L. Bailly, Robert W. Drew, Sr. and William H. Shaw in 1963 and is headquartered in Newburyport, MA.

UFP Technologies Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

UFPTUFP Technologies Inc.

Fundamentals

Latest UFPT News